ATE476530T1 - Neues molekulares target der neurotoxizität - Google Patents

Neues molekulares target der neurotoxizität

Info

Publication number
ATE476530T1
ATE476530T1 AT08160783T AT08160783T ATE476530T1 AT E476530 T1 ATE476530 T1 AT E476530T1 AT 08160783 T AT08160783 T AT 08160783T AT 08160783 T AT08160783 T AT 08160783T AT E476530 T1 ATE476530 T1 AT E476530T1
Authority
AT
Austria
Prior art keywords
pde4b
activity
expression
pde4
sequence
Prior art date
Application number
AT08160783T
Other languages
English (en)
Inventor
Annelies Resink
Ikhlef Ali Ait
Fabien Schweighoffer
Original Assignee
Exonhit Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8866536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE476530(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exonhit Therapeutics Sa filed Critical Exonhit Therapeutics Sa
Application granted granted Critical
Publication of ATE476530T1 publication Critical patent/ATE476530T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
AT08160783T 2001-08-14 2002-08-13 Neues molekulares target der neurotoxizität ATE476530T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0110819A FR2828693B1 (fr) 2001-08-14 2001-08-14 Nouvelle cible moleculaire de la neurotoxicite

Publications (1)

Publication Number Publication Date
ATE476530T1 true ATE476530T1 (de) 2010-08-15

Family

ID=8866536

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02777405T ATE414790T1 (de) 2001-08-14 2002-08-13 Neues molekulares ziel für neurotoxizität
AT08160783T ATE476530T1 (de) 2001-08-14 2002-08-13 Neues molekulares target der neurotoxizität

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02777405T ATE414790T1 (de) 2001-08-14 2002-08-13 Neues molekulares ziel für neurotoxizität

Country Status (15)

Country Link
US (1) US6855736B2 (de)
EP (2) EP1417349B1 (de)
JP (1) JP4527395B2 (de)
CN (2) CN1541278A (de)
AT (2) ATE414790T1 (de)
AU (1) AU2002339017B2 (de)
CA (1) CA2457611C (de)
DE (2) DE60229953D1 (de)
DK (2) DK1417349T3 (de)
ES (2) ES2316625T3 (de)
FR (1) FR2828693B1 (de)
IL (2) IL160141A0 (de)
NZ (1) NZ530939A (de)
PT (2) PT1982704E (de)
WO (1) WO2003016563A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219552A1 (en) * 2001-08-14 2004-11-04 Ali Ait Ikhlef Novel molecular target for neurotoxicity
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
WO2004042390A2 (en) * 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
FR2851247B1 (fr) 2003-02-19 2007-06-29 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de pathologies degeneratives oculaires
ATE337003T1 (de) * 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
FR2856595B1 (fr) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
EP1538218A1 (de) * 2003-12-04 2005-06-08 Erasmus University Medical Center Rotterdam Verfahren zur Diagnose oder Untersuchung entzündlicher Krankheiten
AU2004299277A1 (en) * 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
US20080275078A1 (en) * 2004-03-16 2008-11-06 Glaxo Group Limited Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors
EP1742627A4 (de) 2004-05-06 2009-08-26 Plexxikon Inc Pde4b-hemmer und ihre verwendung
WO2006026754A2 (en) * 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
WO2007071437A2 (en) * 2005-12-22 2007-06-28 Ares Trading S.A. Compositions and methods for treating inflammatory disorders
ES2353093B1 (es) * 2009-05-20 2012-01-03 Consejo Superior De Investigaciones Científicas (Csic) Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
WO2013140785A1 (ja) * 2012-03-18 2013-09-26 国立大学法人九州大学 疾患サンプル分析装置、分析システム及び分析方法
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
MD20170011A2 (ro) 2014-08-06 2017-08-31 Pfizer Inc. Compuşi imidazopiridazinici

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977305A (en) * 1990-04-20 1999-11-02 Cold Spring Harbor Laboratories Cloning by complementation and related processes
US5672622A (en) † 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996020281A1 (en) * 1994-12-23 1996-07-04 Celltech Therapeutics Limited Human phosphodiesterase type ivc, and its production and use
FR2775984B1 (fr) 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EP1141278B1 (de) * 1998-12-30 2008-02-27 Oligos Etc. Inc. Therapeutische pde4d phosphodiesterase inhibitoren
US6334998B1 (en) * 1999-12-07 2002-01-01 Parker Hughes Institute Estrogens for treating ALS
WO2001044449A1 (en) * 1999-12-14 2001-06-21 University Of Utah Research Foundation TWO NOVEL cAMP-SPECIFIC PHOSPHODIESTERASE (PDE4B) ISOFORMS AND RELATED TECHNOLOGY
US20030060487A1 (en) † 2000-04-12 2003-03-27 Bamdad R. Shoshana Treatment of neurodegenerative disease
JP2002020386A (ja) † 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
FR2856595B1 (fr) † 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.

Also Published As

Publication number Publication date
JP2005500066A (ja) 2005-01-06
DK1417349T3 (da) 2009-03-23
US20030064374A1 (en) 2003-04-03
EP1417349A2 (de) 2004-05-12
ES2348348T3 (es) 2010-12-03
CA2457611C (fr) 2013-04-02
DE60237248D1 (de) 2010-09-16
EP1982704A3 (de) 2008-12-17
JP4527395B2 (ja) 2010-08-18
US6855736B2 (en) 2005-02-15
PT1417349E (pt) 2009-02-09
ES2348348T5 (es) 2013-12-04
EP1417349B1 (de) 2008-11-19
CN1541278A (zh) 2004-10-27
WO2003016563A3 (fr) 2004-04-01
CN101632663A (zh) 2010-01-27
DK1982704T3 (da) 2010-10-04
PT1982704E (pt) 2010-10-11
IL160141A0 (en) 2004-06-20
EP1982704B2 (de) 2013-07-24
FR2828693A1 (fr) 2003-02-21
IL160141A (en) 2010-12-30
FR2828693B1 (fr) 2004-06-18
AU2002339017B2 (en) 2007-11-01
EP1982704A2 (de) 2008-10-22
WO2003016563A2 (fr) 2003-02-27
EP1982704B1 (de) 2010-08-04
ES2316625T3 (es) 2009-04-16
CA2457611A1 (fr) 2003-02-27
NZ530939A (en) 2006-11-30
DE60229953D1 (de) 2009-01-02
CN101632663B (zh) 2011-11-30
ATE414790T1 (de) 2008-12-15

Similar Documents

Publication Publication Date Title
DE60237248D1 (de) Neues molekulares Target der Neurotoxizität
EP1562897A4 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
MA27608A1 (fr) Derives d'hydroxyethylamine utilises pour le traitement de la maladie d'alzheimer
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
MA31086B1 (fr) Formulations de doses unitaires et procedes de traitement d'une thrombose avec un inhibiteur oral du facteur xa.
ATE480543T1 (de) Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
AP2004003069A0 (en) 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
MXPA05009535A (es) Compuestos de acido n - alquil - hidroxamico - isoindolilo y sus usos farmaceuticos.
TR200102782T2 (tr) Bisiklik heterosikleler, bu bileşikleri ihtiva eden farmasötik kompozisyonlar
EP1638950A4 (de) Cyclohexylglycinderivate als dipeptidylpeptidaseinhibitoren zur behandlung bzw. prevention von diabetes
EP1689713A4 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
MA28241A1 (fr) Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer
PL377715A1 (pl) Antagoniści CCR1 do leczenia między innymi demielizacyjnej choroby zapalnej
DK1732534T3 (da) Anvendelse af methylenamidderivater ved cardiovaskulære sygdomme
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
MA28562B1 (fr) 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation
ATE448785T1 (de) Behandlung von entzündlicher darmerkrankung
BR9906719A (pt) "n-óxidos de compostos heterocìclicos com atividade inibidora de tnf e de pde-iv"
PT1255734E (pt) Derivados de isatina com actividade neurotrofica
EP1784204A4 (de) Verfahren zur herstellung, prävention, hemmung oder verringerung von schäden an herzgewebe
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
DE60004996D1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen